The interactions between regulatory mechanisms of NLGNs, FMRP, and NRXNs suggest molecular mechanisms underlying FXS and other neurological disorders, offering potential therapeutic targets for future drug development. The gene discussed is FMR1; the disease is fragile X syndrome.